Objective Evidence-based treatment options for late-life treatment-resistant depression
(TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of …

Objective To examine whether psychological well‐being, sleep, and suicidality improved
with treatment with intravenous (IV) ketamine for late‐life treatment‐resistant depression …

Objective To evaluate the safety, tolerability, and effectiveness of repeated doses of
intravenous (IV) ketamine in older adults (ie,≥ 60 years of age) with treatment-resistant …

Late life depression is highly prevalent and asso-ciated with an increased risk of morbidity,
poor physical and cognitive functioning, and suicide. Yet, standard antidepressants are often …

Objective To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-
resistant depression. Secondary aims were to examine if repeated treatments were safe and …

Evidence supporting specific therapies for late-life treatment-resistant depression (LL-TRD)
is necessary. This study used Bayesian adaptive randomization to determine the optimal …

Objective: Ketamine has demonstrated rapid antidepressant effects in patients with
treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this …

Abstract Purpose of Review The purpose of this paper is to provide a review of the use of
ketamine as an antidepressant for treatment-resistant depression (TRD) in the geriatric …

This nonrandomized, multicenter, open-label clinical trial explored the impact of intravenous
(IV) ketamine on cognitive function in adults (n= 74) with treatment-resistant depression …

Rationale Ketamine is a novel, rapid-acting antidepressant for treatment refractory
depression (TRD); however, clinical durability is poor and treatment response trajectories …